Risk communication is usually treated as a prerequisite for informed medication use, yet the act of communicating risk can itself alter treatment experience. Side-effect warnings, numerical presentations, expressions of uncertainty, and the structure of treatment choice may influence expectations, symptom interpretation, perceived control, trust, and subsequent medication behavior. The relevant ethical problem is not whether material risks should be disclosed; they should. The problem is how accurate information can be communicated without unnecessarily transforming possibility into expectation, uncertainty into helplessness, or vigilance into premature treatment withdrawal. Evidence from nocebo research shows that adverse expectations can be learned through clinical and social information and can influence symptom experience, although effects are heterogeneous and should not be confused with pharmacological toxicity. Framing studies similarly suggest that informationally equivalent descriptions may produce different responses, while research on uncertainty shows that consequences depend on what is uncertain, how uncertainty is expressed, and whether the patient receives an actionable management plan. Patient agency is also more complex than maximizing choice: insufficient control can be harmful, but excessive choice may increase cognitive and emotional burden. These processes become clinically important when they influence information seeking, medication initiation, implementation, persistence, or discontinuation. A mechanism-sensitive interpretation therefore requires distinguishing communication-induced nonadherence from informed refusal and from nonadherence driven by genuine treatment burden, access problems, or pharmacological harm. Risk communication should be judged not only by factual accuracy but also by comprehensibility, interpretive effects, preservation of agency, and capacity to support appropriate follow-up.
